NYSE:ABT - Abbott Laboratories Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $132.46
  • Forecasted Upside: 19.44 %
  • Number of Analysts: 14
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.63 (0.57%)

This chart shows the closing price for ABT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Abbott Laboratories Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABT

Analyst Price Target is $132.46
▲ +19.44% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is $132.46, with a high forecast of $150.00 and a low forecast of $112.00. The average price target represents a 19.44% upside from the last price of $110.90.

This chart shows the closing price for ABT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 14 investment analysts is to buy stock in Abbott Laboratories. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/27/2022UBS GroupLower Price TargetBuy$142.00 ➝ $128.00Low
7/22/2022Evercore ISILower Price Target$112.00Low
7/21/2022Morgan StanleyLower Price TargetOverweight$134.00 ➝ $132.00Low
7/21/2022Royal Bank of CanadaLower Price Target$143.00 ➝ $132.00Low
7/21/2022CitigroupLower Price TargetBuy$125.00 ➝ $123.00Low
7/18/2022BTIG ResearchLower Price TargetBuy$130.00 ➝ $126.00Low
7/18/2022Stifel NicolausLower Price Target$136.00 ➝ $126.00Low
7/15/2022Morgan StanleyLower Price TargetOverweight$145.00 ➝ $134.00Low
7/13/2022CowenLower Price Target$150.00 ➝ $130.00Low
7/13/2022CowenLower Price Target$150.00 ➝ $130.00Low
7/5/2022Wolfe ResearchInitiated CoverageUnderperformN/A
6/24/2022BTIG ResearchLower Price TargetBuy$140.00 ➝ $130.00Low
6/7/2022Morgan StanleyLower Price TargetOverweight$151.00 ➝ $145.00Medium
5/17/2022CitigroupLower Price TargetNA$154.00 ➝ $125.00N/A
4/21/2022Royal Bank of CanadaLower Price TargetOutperform$146.00 ➝ $143.00Low
4/21/2022Raymond JamesLower Price TargetOutperform$143.00 ➝ $135.00Low
4/8/2022Wells Fargo & CompanyLower Price TargetOverweight$155.00 ➝ $150.00Medium
3/1/2022Bank of AmericaInitiated CoverageBuy ➝ Buy$140.00Medium
1/27/2022Credit Suisse GroupBoost Price TargetOutperform$138.00 ➝ $139.00Low
1/27/2022UBS GroupBoost Price TargetBuy ➝ Buy$138.00 ➝ $142.00Low
1/27/2022Morgan StanleyLower Price TargetOverweight$157.00 ➝ $151.00Low
1/27/2022Raymond JamesLower Price TargetOutperform$150.00 ➝ $143.00Low
1/26/2022BTIG ResearchLower Price Target$143.00 ➝ $138.00Low
1/10/2022CowenBoost Price Target$140.00 ➝ $150.00Medium
1/7/2022Morgan StanleyBoost Price TargetOverweight$146.00 ➝ $157.00Low
12/23/2021Raymond JamesLower Price Target$150.00 ➝ $134.00Low
12/22/2021Raymond JamesBoost Price TargetOutperform$134.00 ➝ $150.00High
12/9/2021Royal Bank of CanadaInitiated CoverageOutperform$146.00Low
10/27/2021Atlantic SecuritiesUpgradeNeutral ➝ Overweight$144.00High
10/21/2021Morgan StanleyBoost Price TargetOverweight$136.00 ➝ $146.00High
10/21/2021SVB LeerinkReiterated RatingMarket Perform$128.00 ➝ $140.00High
10/21/2021Raymond JamesBoost Price TargetPositive ➝ Outperform$128.00 ➝ $134.00Medium
10/14/2021Redburn PartnersInitiated CoverageNeutral$103.13 ➝ $132.28Low
10/8/2021CowenReiterated RatingBuy$140.00Medium
10/1/2021CitigroupBoost Price TargetBuy$135.00 ➝ $140.00Medium
8/31/2021BTIG ResearchBoost Price TargetBuy$126.00 ➝ $136.00Low
8/23/2021CowenBoost Price TargetPositive ➝ Outperform$125.00 ➝ $140.00Medium
7/23/2021Morgan StanleyBoost Price TargetOverweight$126.00 ➝ $136.00Low
7/23/2021Credit Suisse GroupBoost Price TargetOutperform$120.00 ➝ $130.00Medium
7/23/2021Raymond JamesBoost Price TargetOutperform$116.00 ➝ $128.00Medium
7/20/2021SVB LeerinkBoost Price TargetMarket Perform$115.00 ➝ $128.00Low
7/12/2021Wells Fargo & CompanyBoost Price TargetMarket Perform ➝ Overweight$125.00 ➝ $135.00Low
6/2/2021BTIG ResearchLower Price TargetBuy$140.00 ➝ $120.00Medium
6/2/2021Credit Suisse GroupLower Price TargetOutperform$133.00 ➝ $120.00Medium
6/2/2021BarclaysLower Price TargetOverweight$150.00 ➝ $125.00Medium
6/2/2021Wells Fargo & CompanyLower Price TargetOverweight$137.00 ➝ $125.00Medium
6/2/2021Raymond JamesLower Price TargetOutperform$130.00 ➝ $116.00Medium
6/2/2021Morgan StanleyLower Price TargetOverweight$140.00 ➝ $126.00Medium
6/2/2021CitigroupReiterated RatingBuy$138.00 ➝ $125.00Medium
5/24/2021BarclaysInitiated CoverageOverweight$150.00Medium
4/21/2021Morgan StanleyBoost Price TargetOverweight$136.00 ➝ $140.00Medium
4/20/2021William BlairReiterated RatingOutperformLow
4/15/2021Atlantic SecuritiesInitiated CoverageNeutral$122.00High
3/11/2021Raymond JamesBoost Price TargetOutperform$126.00 ➝ $130.00Low
1/28/2021Wells Fargo & CompanyBoost Price Target$128.00 ➝ $137.00Medium
1/28/2021CowenBoost Price TargetOutperform$113.00 ➝ $140.00Medium
1/28/2021Credit Suisse GroupBoost Price TargetOutperform$118.00 ➝ $130.00High
1/28/2021Morgan StanleyBoost Price TargetOverweight$126.00 ➝ $136.00High
1/28/2021SVB LeerinkBoost Price TargetMarket Perform$115.00 ➝ $128.00High
1/28/2021Raymond JamesBoost Price TargetOutperform$114.00 ➝ $126.00High
1/28/2021BTIG ResearchUpgradeNeutral ➝ Buy$140.00High
12/15/2020Morgan StanleyBoost Price TargetOverweight$121.00 ➝ $126.00Low
11/19/2020Morgan StanleyBoost Price TargetOverweight$117.00 ➝ $121.00Low
10/22/2020Jefferies Financial GroupBoost Price TargetBuy$113.00 ➝ $123.00High
10/22/2020Credit Suisse GroupLower Price TargetOutperform$136.00 ➝ $118.00High
10/22/2020Raymond JamesBoost Price TargetMarket Perform ➝ Outperform$102.00 ➝ $114.00High
10/22/2020Morgan StanleyBoost Price TargetOverweight$112.00 ➝ $117.00High
10/22/2020SVB LeerinkBoost Price TargetPositive ➝ Market Perform$110.00 ➝ $115.00High
10/9/2020JPMorgan Chase & Co.Boost Price TargetOverweight$110.00 ➝ $125.00Low
10/7/2020Wells Fargo & CompanyBoost Price TargetOverweight$120.00 ➝ $122.00Low
9/11/2020Wolfe ResearchInitiated CoverageOutperform$124.00Low
9/2/2020The Goldman Sachs GroupSet Price TargetSell$94.00Low
8/31/2020Credit Suisse GroupBoost Price TargetOutperform$109.00 ➝ $136.00Low
8/28/2020CitigroupBoost Price TargetBuy$110.00 ➝ $130.00High
8/27/2020BTIG ResearchReiterated RatingHoldHigh
8/27/2020The Goldman Sachs GroupSet Price TargetSell$94.00Medium
8/27/2020Wells Fargo & CompanyBoost Price Target$107.00 ➝ $115.00Medium
8/27/2020Stifel NicolausBoost Price TargetBuy$108.00 ➝ $115.00Low
8/27/2020Morgan StanleyBoost Price TargetOverweight$106.00 ➝ $112.00Medium
7/23/2020ArgusBoost Price Target$110.00 ➝ $125.00Low
7/20/2020Bank of AmericaBoost Price TargetBuy$95.00 ➝ $110.00Medium
7/17/2020SVB LeerinkBoost Price TargetMarket Perform$97.00 ➝ $110.00High
7/17/2020Morgan StanleyBoost Price TargetOverweight$100.00 ➝ $106.00High
7/17/2020Credit Suisse GroupBoost Price TargetOutperform$106.00 ➝ $109.00High
7/17/2020CitigroupBoost Price TargetBuy$109.00 ➝ $110.00Medium
7/9/2020Wells Fargo & CompanyReiterated RatingBuy$107.00Low
6/25/2020Morgan StanleyLower Price TargetOverweight$108.00 ➝ $100.00High
5/31/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell$84.00Medium
5/22/2020Credit Suisse GroupReiterated RatingBuy$106.00Low
4/20/2020BarclaysBoost Price TargetOverweight$92.00 ➝ $100.00Medium
4/17/2020UBS GroupBoost Price TargetBuy$105.00 ➝ $109.00Low
4/17/2020JPMorgan Chase & Co.Boost Price TargetOverweight$88.00 ➝ $98.00Low
4/17/2020Stifel NicolausBoost Price Target$85.00 ➝ $108.00Low
4/17/2020Credit Suisse GroupBoost Price TargetOutperform$95.00 ➝ $106.00Medium
4/17/2020Raymond JamesBoost Price TargetOverweight ➝ Outperform$92.00 ➝ $102.00Low
4/17/2020CitigroupBoost Price TargetBuy$87.00 ➝ $109.00Medium
4/17/2020Wells Fargo & CompanyBoost Price TargetOverweight$95.00 ➝ $107.00Medium
4/16/2020BTIG ResearchReiterated RatingHoldLow
4/16/2020CfraBoost Price TargetBuy$99.00 ➝ $101.00Low
4/9/2020Wells Fargo & CompanyBoost Price TargetOverweight$92.00 ➝ $95.00Medium
4/9/2020Raymond JamesLower Price TargetOutperform$99.00 ➝ $92.00Medium
4/8/2020Wells Fargo & CompanyReiterated RatingBuyMedium
4/8/2020SVB LeerinkLower Price TargetMarket Perform$102.00 ➝ $93.00High
4/3/2020JPMorgan Chase & Co.Lower Price TargetOverweight$101.00 ➝ $88.00Low
3/30/2020Wells Fargo & CompanyReiterated RatingBuyMedium
3/27/2020CitigroupLower Price TargetBuy$96.00 ➝ $87.00Medium
3/27/2020Morgan StanleyLower Price TargetOverweight$101.00 ➝ $96.00Medium
3/6/2020Credit Suisse GroupLower Price TargetOutperform$104.00 ➝ $94.00High
3/4/2020CitigroupInitiated CoverageBuy$96.00Medium
2/12/2020The Goldman Sachs GroupInitiated CoverageNeutral$96.00Low
2/6/2020BTIG ResearchReiterated RatingHoldLow
1/23/2020JPMorgan Chase & Co.Lower Price Target$96.00 ➝ $101.00Low
1/23/2020UBS GroupBoost Price TargetBuy$99.00 ➝ $105.00Low
1/23/2020Wells Fargo & CompanyBoost Price TargetOverweight$97.00 ➝ $103.00Medium
1/23/2020Raymond JamesBoost Price TargetOutperform$90.00 ➝ $99.00Medium
1/23/2020Stifel NicolausBoost Price TargetBuy$95.00 ➝ $104.00Medium
1/2/2020CitigroupDowngradeNeutral ➝ SellHigh
1/2/2020Evercore ISIDowngradeOutperform ➝ In-LineHigh
1/2/2020GuggenheimDowngradeBuy ➝ NeutralMedium
12/17/2019Morgan StanleyBoost Price TargetOverweight$93.00 ➝ $101.00Medium
10/17/2019William BlairReiterated RatingUnderperformLow
10/17/2019Credit Suisse GroupBoost Price TargetOutperform$95.00 ➝ $98.00Low
10/14/2019Raymond JamesLower Price TargetOutperform$93.00 ➝ $90.00Low
7/18/2019Jefferies Financial GroupBoost Price TargetBuy$80.00 ➝ $98.00Medium
7/18/2019CowenBoost Price TargetOutperform$86.00 ➝ $95.00High
7/18/2019Raymond JamesBoost Price TargetOutperform$87.00 ➝ $93.00Medium
7/18/2019BMO Capital MarketsBoost Price TargetOutperform$87.00 ➝ $94.00Medium
7/16/2019Morgan StanleyBoost Price TargetOverweight$85.00 ➝ $93.00Low
6/13/2019Bank of AmericaReiterated RatingBuy$81.00Low
6/13/2019Wells Fargo & CompanyBoost Price TargetOutperform$89.00 ➝ $91.00Low
4/18/2019William BlairReiterated RatingOutperformN/A
4/15/2019Royal Bank of CanadaBoost Price TargetBuy$82.00Low
3/14/2019Wells Fargo & CompanyReiterated RatingBuyHigh
3/8/2019BarclaysSet Price TargetBuy$84.00Low
2/7/2019Bank of AmericaReiterated RatingBuy ➝ Buy$73.00 ➝ $81.00Low
1/25/2019ArgusBoost Price TargetBuy ➝ In-Line$90.00Low
1/24/2019BTIG ResearchReiterated RatingHoldMedium
1/2/2019GabelliReiterated RatingBuyLow
1/2/2019Morgan StanleyBoost Price TargetOverweight ➝ Overweight$82.00 ➝ $85.00Low
1/2/2019CitigroupDowngradeNeutral ➝ Sell$72.00 ➝ $68.00High
12/17/2018Credit Suisse GroupInitiated CoverageOutperform$82.00Low
12/9/2018The Goldman Sachs GroupUpgradeNeutral ➝ Buy$74.10Low
12/4/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$80.00 ➝ $82.00High
11/30/2018The Goldman Sachs GroupUpgradeNeutral ➝ Buy$78.00 ➝ $81.00Low
11/27/2018UBS GroupInitiated CoverageBuy$83.00High
10/18/2018Jefferies Financial GroupReiterated RatingIn-Line ➝ Buy$80.00High
10/18/2018Raymond JamesBoost Price TargetOutperform ➝ Outperform$77.00 ➝ $79.00High
10/18/2018BTIG ResearchReiterated RatingHoldHigh
10/15/2018BarclaysInitiated CoverageOverweight ➝ Overweight$80.00High
10/11/2018Morgan StanleyBoost Price TargetOverweight$70.00 ➝ $80.00Medium
10/11/2018Royal Bank of CanadaBoost Price TargetOutperform$77.00Low
10/8/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$77.00 ➝ $81.00Low
10/5/2018CowenBoost Price TargetOutperform ➝ Average$72.00 ➝ $86.00Low
9/24/2018Raymond JamesBoost Price TargetOutperform ➝ Outperform$72.00 ➝ $77.00Medium
9/24/2018Wells Fargo & CompanyBoost Price TargetOutperform ➝ Outperform$77.00 ➝ $80.00Medium
7/19/2018Royal Bank of CanadaReiterated RatingBuy$70.00Low
7/19/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$71.00 ➝ $72.00Medium
6/27/2018Sanford C. BernsteinInitiated CoverageOutperform$73.00Medium
4/24/2018CitigroupLower Price TargetNeutral ➝ Neutral$66.00 ➝ $65.00Low
4/22/2018BTIG ResearchReiterated RatingHoldLow
1/30/2018ArgusBoost Price TargetBuy$66.00 ➝ $80.00Low
1/30/2018CitigroupBoost Price TargetNeutral ➝ Neutral$59.00 ➝ $64.00Low
1/25/2018BarclaysBoost Price TargetOverweight ➝ Overweight$66.00 ➝ $70.00Low
1/25/2018GuggenheimReiterated RatingBuy$72.00Low
1/25/2018Royal Bank of CanadaReiterated RatingBuy$67.00Low
1/25/2018SVB LeerinkReiterated RatingMarket Perform$60.00 ➝ $68.00Low
1/25/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$65.00 ➝ $69.00High
1/25/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$67.00 ➝ $70.00High
1/25/2018Wells Fargo & CompanyBoost Price TargetOutperform$66.00 ➝ $70.00Medium
1/25/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$65.00 ➝ $70.00Medium
1/25/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$63.00 ➝ $71.00Medium
1/25/2018William BlairUpgradeMarket Perform ➝ OutperformMedium
1/24/2018Bank of AmericaBoost Price Target$60.00 ➝ $70.00High
1/22/2018BTIG ResearchDowngradeBuy ➝ NeutralMedium
1/19/2018SVB LeerinkReiterated RatingMarket PerformLow
1/9/2018Royal Bank of CanadaReiterated RatingBuy$65.00Low
1/8/2018BarclaysReiterated RatingBuy$66.00Low
1/3/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$64.00Low
1/2/2018JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$60.00 ➝ $60.00Low
1/2/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$67.00Low
12/12/2017BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$58.00 ➝ $65.00Medium
10/19/2017BarclaysReiterated RatingOverweightN/A
10/19/2017CitigroupReiterated RatingNeutralN/A
10/19/2017BMO Capital MarketsReiterated RatingMarket PerformN/A
10/19/2017CowenSet Price TargetBuy$55.00 ➝ $68.00N/A
10/19/2017Stifel NicolausBoost Price TargetBuy ➝ Buy$58.00 ➝ $63.00N/A
10/19/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$55.00 ➝ $60.00N/A
10/19/2017Jefferies Financial GroupReiterated RatingBuy$65.00N/A
10/6/2017JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Neutral$60.00N/A
10/4/2017Bank of AmericaReiterated RatingBuy$56.00 ➝ $60.00N/A
10/3/2017Royal Bank of CanadaReiterated RatingBuy$55.00Low
10/2/2017BMO Capital MarketsReiterated RatingHold$53.00Low
9/28/2017BarclaysBoost Price TargetOverweight$57.00 ➝ $60.00Low
9/28/2017Wells Fargo & CompanyBoost Price TargetOutperform$57.00 ➝ $64.00Low
9/24/2017CowenReiterated RatingBuyLow
9/1/2017BMO Capital MarketsReiterated RatingHold$53.00N/A
8/17/2017CitigroupInitiated CoverageNeutral ➝ Neutral$53.00Medium
8/17/2017CowenReiterated RatingBuy$55.00Medium
(Data available from 8/11/2017 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 14 very positive mentions
  • 31 positive mentions
  • 8 negative mentions
  • 1 very negative mentions
  • 13 very positive mentions
  • 54 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
  • 5 very positive mentions
  • 22 positive mentions
  • 5 negative mentions
  • 6 very negative mentions
  • 6 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
  • 14 very positive mentions
  • 47 positive mentions
  • 8 negative mentions
  • 5 very negative mentions
  • 24 very positive mentions
  • 58 positive mentions
  • 33 negative mentions
  • 25 very negative mentions
  • 4 very positive mentions
  • 24 positive mentions
  • 5 negative mentions
  • 9 very negative mentions
  • 25 very positive mentions
  • 71 positive mentions
  • 17 negative mentions
  • 8 very negative mentions

Current Sentiment

  • 25 very positive mentions
  • 71 positive mentions
  • 17 negative mentions
  • 8 very negative mentions

Recent Stories by Sentiment

Abbott Laboratories logo
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Read More

Today's Range

Now: $110.90
Low: $110.14
High: $111.12

50 Day Range

MA: $109.00
Low: $102.07
High: $117.51

52 Week Range

Now: $110.90
Low: $101.24
High: $142.60


7,421 shs

Average Volume

4,352,761 shs

Market Capitalization

$194.21 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Abbott Laboratories?

The following sell-side analysts have issued reports on Abbott Laboratories in the last year: Atlantic Securities, Bank of America Co., BTIG Research, Citigroup Inc., Cowen Inc, Cowen Inc., Credit Suisse Group AG, Evercore ISI, Morgan Stanley, Raymond James, Redburn Partners, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, UBS Group AG, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for ABT.

What is the current price target for Abbott Laboratories?

16 Wall Street analysts have set twelve-month price targets for Abbott Laboratories in the last year. Their average twelve-month price target is $132.46, suggesting a possible upside of 19.4%. Wells Fargo & Company has the highest price target set, predicting ABT will reach $150.00 in the next twelve months. Evercore ISI has the lowest price target set, forecasting a price of $112.00 for Abbott Laboratories in the next year.
View the latest price targets for ABT.

What is the current consensus analyst rating for Abbott Laboratories?

Abbott Laboratories currently has 1 sell rating, 2 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ABT will outperform the market and that investors should add to their positions of Abbott Laboratories.
View the latest ratings for ABT.

What other companies compete with Abbott Laboratories?

How do I contact Abbott Laboratories' investor relations team?

Abbott Laboratories' physical mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker's listed phone number is (224) 667-6100. The official website for Abbott Laboratories is www.abbott.com. Learn More about contacing Abbott Laboratories investor relations.